<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381964</url>
  </required_header>
  <id_info>
    <org_study_id>9L4</org_study_id>
    <nct_id>NCT02381964</nct_id>
  </id_info>
  <brief_title>The Effects of Differing Cognitive Task Demands on Whole-body Energy Metabolism and Cerebral Blood-flow: Modulation by Multivitamins/Minerals and Coenzyme Q10</brief_title>
  <official_title>Pilot, Randomized, Placebo-controlled, Double-blind, 3-arm Parallel Groups Trial in Healthy Females to Assess Cerebral Haemodynamics and Energy Expenditure During Cognitive Performance After Supplementation With Two Different Multivitamin / Mineral Preparations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northumbria University</source>
  <brief_summary>
    <textblock>
      When completing difficult tasks, the brain requires faster delivery of energy sources (oxygen&#xD;
      and glucose) via the blood. There is evidence to suggest that some nutritional supplements&#xD;
      may increase blood circulation in the brain which can result in improved task performance.&#xD;
      The purpose of the study is to evaluate the effects of a multivitamin/mineral preparation&#xD;
      (containing a range of vitamins and minerals as contained in commonly consumed&#xD;
      multivitamin/minerals available off the shelf) in healthy females on cerebral (brain) blood&#xD;
      flow and energy expenditure during cognitive task performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamins, minerals and CoQ10, exert a number of physiological effects directly relevant to&#xD;
      energy supply and metabolism. Therefore it is hypothesized that the nutritional interventions&#xD;
      in this trial will facilitate brain metabolic substrate distribution and utilisation during&#xD;
      demanding brain activities with a potential benefit on task performance. This pilot,&#xD;
      double-blind, placebo controlled, 3-arm parallel groups trial will utilise two concomitant&#xD;
      non-invasive techniques:&#xD;
&#xD;
        -  Near Infrared Spectroscopy (NIRS) and&#xD;
&#xD;
        -  Indirect Calorimetry (ICa). The NIRS will be utilised to measure the rate of delivery of&#xD;
           metabolic substrates (via cerebral blood flow i.e. concentrations of total-haemoglobin)&#xD;
           and oxygen extraction from the blood (concentration of deoxy-haemoglobin) in the frontal&#xD;
           cortex of the brain during cognitive tasks.&#xD;
&#xD;
      The ICa calculated from exhaled gas analysis will be utilised to quantify the overall&#xD;
      'energy' costs of performance of tasks in terms of oxygen uptake, carbon dioxide production,&#xD;
      energy expenditure, and substrate (fat and carbohydrate) metabolism.&#xD;
&#xD;
      Cognitive tasks of differing levels of difficulty will be utilised with the hypothesis that&#xD;
      energy expenditure parameters and blood flow/oxygen extraction will increase with rising task&#xD;
      demands, and that any treatment related effect will be more evident under conditions of&#xD;
      increased neural activity. The effects on the above mentioned parameters of two&#xD;
      multivitamin/multimineral preparations (MMP) will be compared to placebo subsequent to single&#xD;
      dose administration (acute) and following daily administration over an eight week period&#xD;
      (chronic). The nutritional interventions are expected to improve nutritional status and&#xD;
      thereby facilitate energy supply and metabolism and to have positive impact on the study&#xD;
      parameters. The effects of the nutritional interventions on nutritional status will be&#xD;
      evaluated by measuring the plasma/serum concentrations of a selected subset of analytes. It&#xD;
      is hypothesized that the nutritional status at baseline and after eight week supplementation&#xD;
      period will have an impact on metabolic substrate conversion, oxygen utilisation, cerebral&#xD;
      blood flow and cognitive performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration change in oxygenated hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat oxidation (Indirect calorimetry)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration change in deoxygenated hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration change in total hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration change in oxygenated hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration change in deoxygenated hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration change in total hemoglobin (Near Infrared Spectroscopy)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbohydrate oxidation (Indirect calorimetry)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total energy expenditure (Indirect calorimetry)</measure>
    <time_frame>1 hour post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fat oxidation (Indirect calorimetry)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Carbohydrate oxidation (Indirect calorimetry)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total energy expenditure (Indirect calorimetry)</measure>
    <time_frame>56 days post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial 3 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial 3 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial 7 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial 7 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial 17 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial 17 subtractions accuracy (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-back task accuracy (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-back task reaction time (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-back task accuracy (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-back task reaction time (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop task accuracy (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop task reaction time (Computerised cognitive task)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop task accuracy (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop task reaction time (Computerised cognitive task)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 3 subtractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 7 substractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 17 substractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for 3 back task (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for stroop task (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 3 subtractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 7 subtractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for Serial 17 subtractions (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for 3 back task (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective rating of task difficulty for stroop task (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of energy levels (Computerised Visual Analogue Scale)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of energy levels (Computerised Visual Analogue Scale)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of calmness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of calmness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of contentedness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of contentedness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of alertness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>1 hour post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject ratings of alertness (Computerised Bond-Lader mood scales)</measure>
    <time_frame>56 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Metabolic Processes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1RDA+CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3RDA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supradyn® (1RDA+CoQ10)</intervention_name>
    <arm_group_label>1RDA+CoQ10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supradyn® (3RDA)</intervention_name>
    <arm_group_label>3RDA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy females aged 25 to 50 years.&#xD;
&#xD;
          -  Female subjects of childbearing potential must be using a medically acceptable form of&#xD;
             birth control and have a negative pregnancy test at screening.&#xD;
&#xD;
          -  Subjects agree to abstain throughout the trial from intake of MMP or supplements&#xD;
             containing CoQ10.&#xD;
&#xD;
          -  Body mass index (BMI) in the range of 18.50-34.99 kg/m2 (extremes included; including&#xD;
             normal weight, overweight and class I obese subjects according to WHO BMI&#xD;
             classification (WHO 2004)).&#xD;
&#xD;
          -  Subjects are, in the opinion of the investigator willing to participate in all&#xD;
             scheduled visits, to adhere to the treatment plan, and other trial procedures&#xD;
             according to the protocol.&#xD;
&#xD;
          -  Subjects accept to refrain from alcohol intake 24 hours and to fast 12 hours before&#xD;
             the visits.&#xD;
&#xD;
          -  Subjects do not have any condition which may interfere with the subject's ability to&#xD;
             perform assessments (i.e. colour blindness) and successfully completes training&#xD;
&#xD;
          -  Subjects provide a personally signed and dated informed consent indicating that the&#xD;
             subject has been informed of all pertinent aspects of the trial and understood and&#xD;
             accepts these.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Physical parameters (including vital signs, e.g., blood pressure, pulse rate, respiratory&#xD;
        rate and body temperature) deviating from normal and with clinical relevance.&#xD;
&#xD;
          -  Acute infection at screening or randomization.&#xD;
&#xD;
          -  A history of, neurological or psychiatric diseases excluding anxiety or depression.&#xD;
&#xD;
          -  Current diagnosis of depression or anxiety.&#xD;
&#xD;
          -  A history or current diagnosis of diseases, for which use of MMP might be&#xD;
             contraindicated or utilisation of MMP might be affected (e.g., iron accumulation, iron&#xD;
             utilisation disorders, hypercalcemia, hypercalciuria, impaired renal function,&#xD;
             hypervitaminosis A, hypervitaminosis D).&#xD;
&#xD;
          -  A history of significant head trauma.&#xD;
&#xD;
          -  Smoker (smoking within the last 3 months).&#xD;
&#xD;
          -  Excessive use of caffeine (&gt; 500 mg caffeine per day) from all dietary sources.&#xD;
&#xD;
          -  History of migraines within the last five years.&#xD;
&#xD;
          -  Current intake of pharmaceuticals (with exception of oral contraceptives, or other&#xD;
             routine medications to treat benign conditions, such as antibiotics to treat acne).&#xD;
&#xD;
          -  Habitual intake of MMP and dietary supplements within the last 4 weeks (defined as ≥3&#xD;
             consecutive days or ≥4 days in total per week).&#xD;
&#xD;
          -  Current or history of drug or alcohol abuse in the opinion of the investigator.&#xD;
&#xD;
          -  Current pregnancy or lactation.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to screening.&#xD;
&#xD;
          -  Any condition which may interfere with the subject's ability to perform assessments&#xD;
             (i.e. colour blindness).&#xD;
&#xD;
          -  Any history of hypersensitivity to the investigational medicinal product or its active&#xD;
             or inactive constituents or any food allergy or intolerance.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David O Kennedy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northumbria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain performance and nutrition research centre, Northumbria university</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>David Kennedy</investigator_full_name>
    <investigator_title>Professor David Kennedy</investigator_title>
  </responsible_party>
  <keyword>cerebral blood flow</keyword>
  <keyword>cognitive function</keyword>
  <keyword>vitamins</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>NIRS</keyword>
  <keyword>Indirect calorimetry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

